Skip to main content
. 2011 Nov;6(11):2612–2619. doi: 10.2215/CJN.03910411

Table 1.

General clinical characteristics of the study population stratified by tertiles of serum osteoprotegerin

Characteristic, Mean (±SD) or n (%) Tertile 1 (1.21 to 5.03 pmol/L), n = 117 Tertile 2 (5.05 to 7.45 pmol/L), n = 117 Tertile 3 (7.46 to 22.31 pmol/L), n = 117 Pa
Demographics
    age (years) 56.4 (±11.6) 60.2 (±9.3) 63.6 (±9.1) <0.01
    female gender 29 (24.8) 31 (26.5) 47 (40.2) 0.02
    black race 56 (47.9) 70 (59.8) 73 (62.4) 0.06
Comorbid conditions
    diabetes 44 (37.6) 66 (56.4) 73 (62.4) <0.01
    cardiovascular disease 26 (22.2) 44 (37.6) 53 (45.3) <0.01
    hypertension 99 (84.6) 99 (84.6) 110 (94.0) 0.04
    current/former smoker 52 (44.4) 65 (55.6) 69 (59.0) 0.07
Examination
    body mass index (kg/m2) 31.7 (±7.0) 31.9 (±7.2) 30.9 (±6.2) 0.54
    waist circumference (cm) 107.5 (±17.1) 107.8 (±17.3) 105.2 (±16.9) 0.44
    systolic BP (mmHg) 124 (±21) 131 (±21) 136 (±21) <0.01
    diastolic BP (mmHg) 75 (±15) 76 (±14) 73 (±14) 0.43
    aortic pulse wave velocity (m/s)b,c 8.0 (7.0, 9.8) 9.4 (7.9, 11.9) 10.6 (9.0, 12.2) <0.01
Laboratory
    albuminuria
        <30 mg/day 50 (52.1) 40 (41.7) 45 (45.0)
        30 to 299 mg/day 24 (25.0) 31 (32.3) 27 (27.0) 0.62
        ≥300 mg/day 22 (22.9) 25 (26.0) 28 (28.0)
    eGFR (ml/min per 1.73 m2) 51.5 (±13.9) 48.3 (±13.6) 42.8 (±13.5) <0.01
    serum albumin (g/dl) 4.0 (±0.37) 3.9 (±0.40) 3.8 (±0.36) <0.01
    hs-CRP (mg/L)b 2.2 (1.0, 6.1) 2.5 (0.9, 5.5) 2.4 (1.0, 6.8) 0.63
Medications
    ACE inhibitors 61 (52.6) 57 (49.6) 51 (44.0) 0.41
    lipid-lowering medications 62 (53.5) 76 (66.1) 73 (62.9) 0.12

eGFR, estimated GFR; hs-CRP, high-sensitivity C-reactive protein; ACE, angiotensin-converting enzyme.

a

P value using ANOVA (continuous variables) or Pearson's chi-squared test (categorical variables).

b

Values presented as median (interquartile range). P-values calculated from log-transformed variable.

c

Among n = 226 with concurrent pulse wave velocity available.

HHS Vulnerability Disclosure